GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention

Author(s): Dery J.P., Harrington R.A., Tcheng J.E.

Journal Name: Current Pharmaceutical Design

Volume 10 , Issue 4 , 2004

Become EABM
Become Reviewer
Call for Editor


Cumulative scientific evidence gathered over the past ten years has confirmed the role of platelet GP IIb / IIIa inhibitors in reducing ischemic complications of patients undergoing percutaneous coronary intervention (PCI). Recently, mortality data available on more than 20,000 patients enrolled in randomized clinical trials suggest that GP IIb / IIIa blockade also improves short and long-term survival after PCI. Despite convincing arguments, GP IIb / IIIa inhibitors are still inconsistently administered in patients undergoing coronary intervention. The following review will discuss the scientific grounds and the principal controversies surrounding the use of these compounds in patients undergoing elective percutaneous coronary intervention.

Keywords: Coronary Intervention, IIIa inhibitors, GP IIb

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [387 - 398]
Pages: 12
DOI: 10.2174/1381612043453306
Price: $65

Article Metrics

PDF: 2